{"transactions":[{"id":723014,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T20:04:23.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":2875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":2875,"derivative":{"exercise_price":3.85,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":2875},"source":{"system":"sec-edgar","filing":"0001237401-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000123740126000002/ownership.xml","form_type":"4"}},{"id":723013,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T20:04:23.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":2875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On May 29, 2026, the common stock of the Issuer underwent a 1-for-8 reverse stock split (the \"Reverse Stock Split\"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split."}],"balance_after":11522,"source":{"system":"sec-edgar","filing":"0001237401-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000123740126000002/ownership.xml","form_type":"4"}},{"id":940865,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-12T21:05:09.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030."}],"balance_after":375000,"derivative":{"exercise_price":11.21,"expiration_date":"2036-01-07","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001193125-26-010361","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000119312526010361/ownership.xml","form_type":"4"}},{"id":1099484,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-30T20:16:28.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":23000,"derivative":{"exercise_price":0.74,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0000950170-25-091589","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017025091589/ownership.xml","form_type":"4"}},{"id":1099483,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-30T20:16:28.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":69183,"source":{"system":"sec-edgar","filing":"0000950170-25-091589","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017025091589/ownership.xml","form_type":"4"}},{"id":1259698,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-19T23:25:30.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":365800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":365800,"derivative":{"exercise_price":3.29,"expiration_date":"2035-02-14","underlying":"Common Shares","underlying_shares":365800},"source":{"system":"sec-edgar","filing":"0001447028-25-000050","document":"wk-form4_1740007524.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702825000050/wk-form4_1740007524.xml","form_type":"4"}},{"id":1259697,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2025-02-19T23:25:30.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":90100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction."}],"balance_after":249824,"source":{"system":"sec-edgar","filing":"0001447028-25-000050","document":"wk-form4_1740007524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702825000050/wk-form4_1740007524.xml","form_type":"4"}},{"id":1281714,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2025-02-05T21:02:55.000Z","date":"2025-02-04","kind":"sale","planned":true,"acquired":false,"shares":22183,"price":3.283,"value":72826.789,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 6, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units."}],"balance_after":159724,"source":{"system":"sec-edgar","filing":"0001447028-25-000040","document":"wk-form4_1738789366.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702825000040/wk-form4_1738789366.xml","form_type":"4"}},{"id":1472331,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-06-21T20:10:30.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":23000,"derivative":{"exercise_price":1.88,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0000950170-24-076239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017024076239/ownership.xml","form_type":"4"}},{"id":1472330,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T20:10:30.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":46183,"source":{"system":"sec-edgar","filing":"0000950170-24-076239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017024076239/ownership.xml","form_type":"4"}},{"id":1658670,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-06T00:54:49.000Z","date":"2024-02-01","kind":"grant","planned":true,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":450000,"derivative":{"exercise_price":2.4,"expiration_date":"2034-02-01","underlying":"Common Shares","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001447028-24-000027","document":"wk-form4_1707180869.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702824000027/wk-form4_1707180869.xml","form_type":"4"}},{"id":1658669,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2024-02-06T00:54:49.000Z","date":"2024-02-02","kind":"sale","planned":true,"acquired":false,"shares":9593,"price":2.3125,"value":22183.8125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on  March 6, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of a previous grant of restricted stock units."}],"balance_after":181907,"source":{"system":"sec-edgar","filing":"0001447028-24-000027","document":"wk-form4_1707180869.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702824000027/wk-form4_1707180869.xml","form_type":"4"}},{"id":1658668,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2024-02-06T00:54:49.000Z","date":"2024-02-01","kind":"grant","planned":true,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction."}],"balance_after":191500,"source":{"system":"sec-edgar","filing":"0001447028-24-000027","document":"wk-form4_1707180869.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702824000027/wk-form4_1707180869.xml","form_type":"4"}},{"id":1845516,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-23T20:08:00.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":23183,"source":{"system":"sec-edgar","filing":"0000950170-23-029609","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017023029609/ownership.xml","form_type":"4"}},{"id":1850104,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-06-21T00:06:59.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":2.74,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-23-029046","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017023029046/ownership.xml","form_type":"4"}},{"id":2032761,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T21:11:02.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":316000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":316000,"derivative":{"exercise_price":2.9,"expiration_date":"2033-02-01","underlying":"Common Shares","underlying_shares":316000},"source":{"system":"sec-edgar","filing":"0001447028-23-000009","document":"wf-form4_167545863617086.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702823000009/wf-form4_167545863617086.xml","form_type":"4"}},{"id":2032760,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2023-02-03T21:11:02.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":79000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction."}],"balance_after":79000,"source":{"system":"sec-edgar","filing":"0001447028-23-000009","document":"wf-form4_167545863617086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702823000009/wf-form4_167545863617086.xml","form_type":"4"}},{"id":2209155,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-11T20:05:27.000Z","date":"2022-07-11","kind":"other","acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":2.98,"underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001104659-22-078789","document":"tm2220760-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465922078789/tm2220760-3_4seq1.xml","form_type":"4"}},{"id":2209154,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-11T20:05:27.000Z","date":"2022-07-11","kind":"other","acquired":false,"shares":26583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":2.44,"underlying":"Common Stock","underlying_shares":26583},"source":{"system":"sec-edgar","filing":"0001104659-22-078789","document":"tm2220760-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465922078789/tm2220760-3_4seq1.xml","form_type":"4"}},{"id":2209153,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-11T20:05:27.000Z","date":"2022-07-11","kind":"disposition_to_issuer","acquired":false,"shares":27500,"price":2.2,"value":60500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the \"Merger\") became effective (the \"Effective Time\") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the \"Merger\") became effective (the \"Effective Time\") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-22-078789","document":"tm2220760-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465922078789/tm2220760-3_4seq1.xml","form_type":"4"}},{"id":2209152,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-11T20:05:27.000Z","date":"2022-07-07","kind":"other","acquired":false,"shares":22000,"price":2.2,"value":48400.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of to Innoviva Merger Sub, Inc. (\"Merger Sub\"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. (\"Innoviva\"), and Merger Sub (the \"Merger Agreement\"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of to Innoviva Merger Sub, Inc. (\"Merger Sub\"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. (\"Innoviva\"), and Merger Sub (the \"Merger Agreement\"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the \"Offer Price\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-22-078789","document":"tm2220760-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465922078789/tm2220760-3_4seq1.xml","form_type":"4"}},{"id":2224417,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T20:06:42.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":1.78,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-22-038666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919122038666/doc4.xml","form_type":"4"}},{"id":2224416,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-22T20:06:42.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":13183,"source":{"system":"sec-edgar","filing":"0001209191-22-038666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919122038666/doc4.xml","form_type":"4"}},{"id":2394153,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T21:01:22.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":5769,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 7,500 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 5,769 shares of issuer's common stock, having an exercise price of $2.44 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date."}],"balance_after":5769,"derivative":{"exercise_price":2.44,"expiration_date":"2031-07-15","underlying":"Common Stock","underlying_shares":5769},"source":{"system":"sec-edgar","filing":"0001104659-22-023768","document":"tm226724-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465922023768/tm226724-2_4seq1.xml","form_type":"4"}},{"id":2394152,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T21:01:22.000Z","date":"2021-07-16","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 7,500 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 5,769 shares of issuer's common stock, having an exercise price of $2.44 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option provided for vesting as follows:  The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the  next annual stockholder meeting, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":6.12,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-22-023768","document":"tm226724-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465922023768/tm226724-2_4seq1.xml","form_type":"4"}},{"id":2394151,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T21:01:22.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":11538,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 shares of issuer's common stock granted to the Reporting Person on January 18, 2019. In exchange, the Reporting Person received a replacement option for 11,538 shares of issuer's common stock, having an exercise price of $2.44 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date."}],"balance_after":11538,"derivative":{"exercise_price":2.44,"expiration_date":"2031-07-15","underlying":"Common Stock","underlying_shares":11538},"source":{"system":"sec-edgar","filing":"0001104659-22-023768","document":"tm226724-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465922023768/tm226724-2_4seq1.xml","form_type":"4"}},{"id":2394150,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T21:01:22.000Z","date":"2021-07-16","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 shares of issuer's common stock granted to the Reporting Person on January 18, 2019. In exchange, the Reporting Person received a replacement option for 11,538 shares of issuer's common stock, having an exercise price of $2.44 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option provided for vesting as follows: The shares subject to this option will vest in full on January 1, 2020, subject to the Reporting Person's continued service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.66,"expiration_date":"2029-01-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-22-023768","document":"tm226724-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465922023768/tm226724-2_4seq1.xml","form_type":"4"}},{"id":2394149,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to  Buy)","published_at":"2022-02-15T21:01:22.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":9276,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date."}],"balance_after":9276,"derivative":{"exercise_price":2.44,"expiration_date":"2031-07-15","underlying":"Common Stock","underlying_shares":9276},"source":{"system":"sec-edgar","filing":"0001104659-22-023768","document":"tm226724-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465922023768/tm226724-2_4seq1.xml","form_type":"4"}},{"id":2394148,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T21:01:22.000Z","date":"2021-07-16","kind":"disposition_to_issuer","acquired":false,"shares":12060,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 12,060 shares of issuer's common stock granted to the Reporting Person on May 1, 2018. In exchange, the Reporting Person received a replacement option for 9,276 shares of issuer's common stock, having an exercise price of $2.44 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option will vest on May 1, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the last day of the month, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":0,"derivative":{"exercise_price":6.85,"expiration_date":"2028-04-30","underlying":"Common Stock","underlying_shares":12060},"source":{"system":"sec-edgar","filing":"0001104659-22-023768","document":"tm226724-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465922023768/tm226724-2_4seq1.xml","form_type":"4"}},{"id":2430304,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-20T22:55:10.000Z","date":"2022-01-20","kind":"grant","acquired":true,"shares":285000,"price":2.81,"value":800850.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options will vest and become exercisable 1/48th each month over the four year period."}],"balance_after":285000,"derivative":{"exercise_price":2.81,"expiration_date":"2032-01-20","underlying":"Common Shares","underlying_shares":285000},"source":{"system":"sec-edgar","filing":"0001447028-22-000011","document":"wf-form4_164271929611191.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702822000011/wf-form4_164271929611191.xml","form_type":"4"}},{"id":2431989,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-19T21:01:18.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This award vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service as a director of the Company."}],"balance_after":49500,"source":{"system":"sec-edgar","filing":"0001104659-22-005412","document":"tm223320-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465922005412/tm223320-3_4seq1.xml","form_type":"4"}},{"id":2661561,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T12:31:01.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":7.51,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-041824","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919121041824/doc4.xml","form_type":"4"}},{"id":2760756,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T14:33:46.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"source":{"system":"sec-edgar","filing":"0001104659-21-045912","document":"tm2111994-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465921045912/tm2111994-1_4seq1.xml","form_type":"4"}},{"id":2766655,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T20:04:04.000Z","date":"2020-07-06","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant; provided, that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":55000,"derivative":{"exercise_price":0.73,"expiration_date":"2030-07-05","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-21-023761","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919121023761/doc4a.xml","form_type":"4/A","original_submission_date":"2020-07-06"}},{"id":2854286,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2021-02-17T22:06:18.000Z","date":"2021-02-13","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest and become exercisable 1/48th each month over the four year period."}],"balance_after":250000,"derivative":{"exercise_price":4.33,"expiration_date":"2031-02-13","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001447028-21-000012","document":"wf-form4_161359955145004.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702821000012/wf-form4_161359955145004.xml","form_type":"4"}},{"id":3011540,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-06T20:32:44.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the  next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date."}],"balance_after":11000,"derivative":{"exercise_price":2.98,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001104659-20-112660","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465920112660/a4.xml","form_type":"4"}},{"id":3086794,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-08T20:11:17.000Z","date":"2020-07-06","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":45000,"derivative":{"exercise_price":0.73,"expiration_date":"2030-07-05","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-20-041739","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919120041739/doc4.xml","form_type":"4"}},{"id":3262956,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2020-02-19T13:03:32.000Z","date":"2020-02-17","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest and become exercisable 1/48th each month over the four year period."}],"balance_after":100000,"derivative":{"exercise_price":3.35,"expiration_date":"2030-02-17","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001447028-20-000027","document":"wf-form4_158211739512646.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702820000027/wf-form4_158211739512646.xml","form_type":"4"}},{"id":3481129,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-21T20:04:07.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the  next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":6.12,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-19-037006","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000110465919037006/a4.xml","form_type":"4"}},{"id":3482549,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-20T17:34:27.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":45000,"derivative":{"exercise_price":1.29,"expiration_date":"2029-06-17","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-19-038197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919119038197/doc4.xml","form_type":"4"}},{"id":3612034,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-03-05T23:04:52.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":137500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable in three equal annual installments beginning March 1, 2020."}],"balance_after":137500,"derivative":{"exercise_price":4.57,"expiration_date":"2029-03-01","underlying":"Common Shares","underlying_shares":137500},"source":{"system":"sec-edgar","filing":"0001123292-19-000431","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000112329219000431/edgar.xml","form_type":"4"}},{"id":3690530,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-22T21:58:55.000Z","date":"2019-01-18","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on January 1, 2020, subject to the Reporting Person continuing to provide service through such date."}],"balance_after":15000,"derivative":{"exercise_price":5.66,"expiration_date":"2029-01-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-004768","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000120919119004768/doc4.xml","form_type":"4"}},{"id":3704417,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-04T13:08:04.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":22500,"derivative":{"exercise_price":0.5441,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-19-001639","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919119001639/doc4.xml","form_type":"4"}},{"id":3886026,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-06-21T21:53:34.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows:  1/3 on 6/11/2019; 1/3 on 6/11/2020; and 1/3 on 6/11/2021."}],"balance_after":200000,"derivative":{"exercise_price":6.75,"expiration_date":"2028-06-19","underlying":"Common Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001140361-18-029511","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000114036118029511/doc1.xml","form_type":"4"}},{"id":4001229,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2018-03-12T12:52:27.000Z","date":"2018-03-08","kind":"purchase","acquired":true,"shares":5325,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase on March 8, 2018, of 11,834 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant)."}],"balance_after":5325,"derivative":{"exercise_price":2,"exercise_date":"2018-03-08","expiration_date":"2023-03-08","underlying":"Common Stock","underlying_shares":5325},"source":{"system":"sec-edgar","filing":"0001209191-18-018711","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919118018711/doc4.xml","form_type":"4"}},{"id":4001228,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2018-03-12T12:52:27.000Z","date":"2018-03-08","kind":"purchase","acquired":true,"shares":8875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase on March 8, 2018, of 11,834 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant)."}],"balance_after":8875,"derivative":{"exercise_price":1.85,"exercise_date":"2018-03-08","expiration_date":"2019-03-14","underlying":"Common Stock","underlying_shares":8875},"source":{"system":"sec-edgar","filing":"0001209191-18-018711","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919118018711/doc4.xml","form_type":"4"}},{"id":4001227,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-12T12:52:27.000Z","date":"2018-03-08","kind":"purchase","acquired":true,"shares":11834,"price":1.69,"value":19999.46,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase on March 8, 2018, of 11,834 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant)."}],"balance_after":31834,"source":{"system":"sec-edgar","filing":"0001209191-18-018711","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919118018711/doc4.xml","form_type":"4"}},{"id":4107777,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-04T17:22:52.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":19989,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant; provided, that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":19989,"derivative":{"exercise_price":2.28,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":19989},"source":{"system":"sec-edgar","filing":"0001209191-18-001740","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919118001740/doc4.xml","form_type":"4"}},{"id":4274673,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-22T12:58:57.000Z","date":"2017-06-21","kind":"purchase","acquired":true,"shares":20000,"price":1.75,"value":35000.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001178253-17-000011","document":"wf-form4_149813632239136.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000117825317000011/wf-form4_149813632239136.xml","form_type":"4"}},{"id":4477187,"issuer":{"id":12414,"kind":"organization","name":"Unilife Corp","symbol":"UNIS"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-30T20:45:28.000Z","date":"2017-01-26","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in installments as follows: 37,500 shares on January 26, 2018; 37,500 shares on January 26, 2019; and 75,000 shares on January 26, 2020."}],"balance_after":150000,"derivative":{"exercise_price":2.53,"expiration_date":"2027-01-26","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-17-002222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1476170/000089924317002222/doc4.xml","form_type":"4"}},{"id":4498856,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-01-05T23:16:06.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":14499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant; provided, that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":14499,"derivative":{"exercise_price":3.4,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":14499},"source":{"system":"sec-edgar","filing":"0001628280-17-000107","document":"wf-form4_148365815249164.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000162828017000107/wf-form4_148365815249164.xml","form_type":"4"}}]}